Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Rituximab in multiple sclerosis - Fatigue, cognition, and efficacy

Hellgren, Johan LU (2025) In Lund University, Faculty of Medicine Doctoral Dissertation Series
Abstract
Background: Multiple sclerosis (MS) is an inflammatory, demyelinating disease affecting the central nervous system. Fatigue and impaired information processing speed (IPS) are the most debilitating symptoms of MS. Natalizumab (NTZ) and rituximab (RTX), currently Sweden’s two most-prescribed drugs for MS treatment, are known to almost completely ameliorate clinical and radiological relapse activity in patients with RRMS. However, the effects on fatigue and IPS are unclear. RTX remains an offlabel therapy for MS.

Methods: This thesis comprises two study designs. The first is a retrospective observational study evaluating the safety and efficacy of RTX in 83 patients with MS at the Helsingborg General Hospital. The second is a... (More)
Background: Multiple sclerosis (MS) is an inflammatory, demyelinating disease affecting the central nervous system. Fatigue and impaired information processing speed (IPS) are the most debilitating symptoms of MS. Natalizumab (NTZ) and rituximab (RTX), currently Sweden’s two most-prescribed drugs for MS treatment, are known to almost completely ameliorate clinical and radiological relapse activity in patients with RRMS. However, the effects on fatigue and IPS are unclear. RTX remains an offlabel therapy for MS.

Methods: This thesis comprises two study designs. The first is a retrospective observational study evaluating the safety and efficacy of RTX in 83 patients with MS at the Helsingborg General Hospital. The second is a cross-sectional multicenter study including 128 patients with relapsing-remitting MS, treated with either NTZ or RTX for at least 24 months. Fatigue, IPS, and levels of the astrocyte marker, glial fibrillary acidic protein (GFAP), and axonal damage marker, neurofilament light (NfL), in the cerebrospinal fluid and plasma were compared in both treatment groups. IPS was assessed using the Symbol Digit Modalities Test (SDMT) and fatigue, with the Fatigue Scale for Motor and Cognitive Functions (FSMC). Fatigue and IPS were explored in relation to GFAP and NfL.

Results: In the retrospective study, RTX significantly reduced relapses and new lesions on MRI. Serious adverse events were few. In the comparative cross-sectional study, no between-group differences were found regarding fatigue. Participants treated with NTZ performed significantly better on the SDMT than
those treated with RTX. Plasma GFAP and NfL levels did not significantly differ between the treatment groups. Neither GFAP nor NfL exhibited significant associations with fatigue or IPS.

Conclusion: RTX is a safe and effective option for treating relapsing-remitting MS. The significantly better performance on SDMT of patients treated with NTZ may have been influenced by repeated exposure to the test, i.e., practice effects. Longitudinal controlled studies are needed to further evaluate the effects of high-efficacy disease modifying therapies on fatigue and IPS in MS. (Less)
Please use this url to cite or link to this publication:
author
supervisor
opponent
  • Professor emeritus Fredrikson, Sten, Department of Clinical Neuroscience, Karolinska Institute
organization
publishing date
type
Thesis
publication status
published
subject
keywords
Multiple sclerosis, Rituximab, Natalizumab, Fatigue, Information processing speed, GFAP, NFL, Oligocloncal bands, Kappa free light chain, Patient Reported Outcome Measures (PROMs)
in
Lund University, Faculty of Medicine Doctoral Dissertation Series
issue
135
pages
90 pages
publisher
Lund University, Faculty of Medicine
defense location
Medicinhistoriska muséet, Bergaliden 20, Helsingborg
defense date
2025-12-05 13:00:00
ISSN
1652-8220
ISBN
978-91-8021-788-0
language
English
LU publication?
yes
id
256a3518-f009-436f-9da4-914ce6e90612
date added to LUP
2025-11-01 15:02:37
date last changed
2025-11-14 08:23:56
@phdthesis{256a3518-f009-436f-9da4-914ce6e90612,
  abstract     = {{Background: Multiple sclerosis (MS) is an inflammatory, demyelinating disease affecting the central nervous system. Fatigue and impaired information processing speed (IPS) are the most debilitating symptoms of MS. Natalizumab (NTZ) and rituximab (RTX), currently Sweden’s two most-prescribed drugs for MS treatment, are known to almost completely ameliorate clinical and radiological relapse activity in patients with RRMS. However, the effects on fatigue and IPS are unclear. RTX remains an offlabel therapy for MS. <br/><br/>Methods: This thesis comprises two study designs. The first is a retrospective observational study evaluating the safety and efficacy of RTX in 83 patients with MS at the Helsingborg General Hospital. The second is a cross-sectional multicenter study including 128 patients with relapsing-remitting MS, treated with either NTZ or RTX for at least 24 months. Fatigue, IPS, and levels of the astrocyte marker, glial fibrillary acidic protein (GFAP), and axonal damage marker, neurofilament light (NfL), in the cerebrospinal fluid and plasma were compared in both treatment groups. IPS was assessed using the Symbol Digit Modalities Test (SDMT) and fatigue, with the Fatigue Scale for Motor and Cognitive Functions (FSMC). Fatigue and IPS were explored in relation to GFAP and NfL. <br/><br/>Results: In the retrospective study, RTX significantly reduced relapses and new lesions on MRI. Serious adverse events were few. In the comparative cross-sectional study, no between-group differences were found regarding fatigue. Participants treated with NTZ performed significantly better on the SDMT than<br/>those treated with RTX. Plasma GFAP and NfL levels did not significantly differ between the treatment groups. Neither GFAP nor NfL exhibited significant associations with fatigue or IPS. <br/><br/>Conclusion: RTX is a safe and effective option for treating relapsing-remitting MS. The significantly better performance on SDMT of patients treated with NTZ may have been influenced by repeated exposure to the test, i.e., practice effects. Longitudinal controlled studies are needed to further evaluate the effects of high-efficacy disease modifying therapies on fatigue and IPS in MS.}},
  author       = {{Hellgren, Johan}},
  isbn         = {{978-91-8021-788-0}},
  issn         = {{1652-8220}},
  keywords     = {{Multiple sclerosis; Rituximab; Natalizumab; Fatigue; Information processing speed; GFAP; NFL; Oligocloncal bands; Kappa free light chain; Patient Reported Outcome Measures (PROMs)}},
  language     = {{eng}},
  number       = {{135}},
  publisher    = {{Lund University, Faculty of Medicine}},
  school       = {{Lund University}},
  series       = {{Lund University, Faculty of Medicine Doctoral Dissertation Series}},
  title        = {{Rituximab in multiple sclerosis -  Fatigue, cognition, and efficacy}},
  url          = {{https://lup.lub.lu.se/search/files/231916510/avhandling_Johan_Hellgren_LUCRIS.pdf}},
  year         = {{2025}},
}